Lido Advisors
ALNY icon

Lido Advisors’s Alnylam Pharmaceuticals ALNY Stock Holding History

Lido Advisors’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-1,180
Closed -$390K – 2130
2026
Q1 		$390K Buy
1,180
+463
+65% +$158K ﹤0.01% 1433
2025
Q4 		$312K Buy
717
+59
+9% +$26.1K ﹤0.01% 1548
2025
Q3 		$300K Buy
+658
New +$268K ﹤0.01% 1493

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Lido Advisors's ALNY Position: Q2 2026 in Review

Lido Advisors sold out of Alnylam Pharmaceuticals (ALNY) in Q2 2026, closing a stake of 1,180 shares — an estimated $390K sold.

Lido Advisors first reported a position in ALNY in Q3 2025 and held it in 3 quarters. The position peaked at $390K in Q1 2026. 784 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

  • Lido Advisors reported no remaining Alnylam Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Lido Advisors sold 1,180 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $390K.
  • Lido Advisors first reported a position in Alnylam Pharmaceuticals in Q3 2025 and held it in 3 quarters.
  • Lido Advisors's Alnylam Pharmaceuticals position peaked at $390K in Q1 2026.
  • 784 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on Lido Advisors's 13F filing for Q2 2026, filed 7 Aug 2026.